Any practitioner with a standard DEA registration that includes Schedule III authority can now prescribe buprenorphine for opioid use disorder, with no special waiver required. The old X-waiver system was eliminated in January 2023 by the MAT Act. What remains is a structured clinical process: diagnosing opioid use disorder, assessing withdrawal severity, choosing the right formulation, inducting at the correct time, and managing ongoing maintenance dosing.
Current Federal Requirements
Section 1262 of the Consolidated Appropriations Act of 2023 removed the requirement for practitioners to submit a Notice of Intent (the former DATA-Waiver) to prescribe buprenorphine. SAMHSA no longer accepts waiver applications, and the DATA-Waiver registration number is no longer required on prescriptions. Opioid use disorder prescriptions now only require a standard DEA registration number.
You still need a valid DEA registration and must be authorized to prescribe buprenorphine under the laws of the state where you practice. A separate provision requires practitioners who are new or renewing DEA registrants (as of June 27, 2023) to meet one of these conditions: completion of at least eight hours of training on substance use disorders, board certification in addiction medicine or addiction psychiatry, or graduation within five years from an accredited medical, nursing, or physician assistant program that included at least eight hours of substance use disorder curriculum.
Diagnosing Opioid Use Disorder
The DSM-5 defines opioid use disorder as a pattern of opioid use leading to clinically significant problems or distress, with at least 2 of 11 criteria present within a 12-month period. Severity breaks down by count: mild is 2 to 3 criteria, moderate is 4 to 5, and severe is 6 or more.
The 11 criteria cover a broad range of behaviors and consequences. These include taking opioids in larger amounts or for longer than intended, unsuccessful efforts to cut down, spending excessive time obtaining or recovering from opioids, and experiencing cravings. Functional criteria include problems at work or school, giving up activities, continued use despite social or health consequences, and use in physically hazardous situations like driving. The final two criteria, tolerance and withdrawal, should not be counted toward a diagnosis when a patient is taking opioids as prescribed under medical supervision.
Choosing the Right Formulation
The standard formulation for most patients is the combination product containing both buprenorphine and naloxone (an opioid blocker included to discourage misuse by injection). This combination is available as sublingual tablets and films. The monoproduct, buprenorphine without naloxone, is generally reserved for pregnant patients, as some clinicians prefer it to avoid any theoretical risk from the naloxone component during pregnancy.
Timing Induction to Avoid Precipitated Withdrawal
Buprenorphine is a partial opioid agonist, meaning it activates opioid receptors but less strongly than full agonists like heroin, fentanyl, or oxycodone. If given while a full agonist is still occupying the receptors, buprenorphine can displace it and abruptly drop the level of receptor activation, triggering precipitated withdrawal. This is different from ordinary withdrawal: symptoms come on rapidly, usually within one to two hours of the first dose, and can include severe nausea, vomiting, diarrhea, abdominal cramps, dilated pupils, runny nose, body aches, and yawning.
To prevent this, patients need to be in a sufficient state of withdrawal before the first dose. The Clinical Opiate Withdrawal Scale (COWS) is the standard tool for measuring withdrawal severity on a numerical scale. A score of 5 to 12 indicates mild withdrawal, 13 to 24 is moderate, 25 to 36 is moderately severe, and above 36 is severe. Most induction protocols call for a COWS score above a moderate threshold before the first dose is given.
For patients using short-acting opioids, this typically means waiting at least 12 to 24 hours after the last use. For long-acting opioids like methadone, the required abstinence period is longer, often 36 to 72 hours. Patients using fentanyl (particularly illicit fentanyl, which accumulates in fat tissue) may need a longer waiting period, and some clinicians are now using low-dose or “micro-dosing” induction protocols to manage this challenge.
Day 1 Induction Dosing
Once the patient’s COWS score confirms adequate withdrawal, the standard approach is to start with 4 mg of buprenorphine (sublingual). After one hour, if withdrawal symptoms persist, a second 4 mg dose is given. Additional 4 mg doses can follow at one- to two-hour intervals if needed, up to a maximum of 16 mg on the first day.
This stepwise approach allows you to titrate based on the patient’s response rather than committing to a large initial dose. Some patients feel significant relief after just 4 to 8 mg, while others need the full 16 mg. The goal by the end of the first day is symptom control, not necessarily finding the final maintenance dose.
Stabilization and Maintenance Dosing
Over the following days, the dose is adjusted upward as needed. Most patients stabilize on a daily dose between 12 and 16 mg, though the effective maintenance range is broad. Clinical evidence consistently shows dose-dependent benefits up to at least 32 mg per day, including greater suppression of withdrawal symptoms, reduced cravings, better blockade of the euphoric effects of other opioids, and improved retention in treatment.
The FDA product label identifies 16 mg per day as a target dose and 24 mg per day as the labeled maximum, but multiple clinical guidelines from SAMHSA, the VA/DoD, and international bodies recommend doses up to 32 mg per day when clinically indicated. A 2023 review in the Journal of Addiction Medicine found robust evidence that limiting patients to 16 mg when they need more can compromise outcomes. If a patient continues to experience cravings or return to use at lower doses, increasing to 24 or 32 mg per day is well supported.
An adequate maintenance dose should accomplish three things: suppress withdrawal symptoms and cravings so the patient is not driven back to opioid use, block the euphoric effect of any illicit opioids so using them feels unrewarding, and reduce the risk of respiratory depression from those opioids by occupying the receptors.
Managing Precipitated Withdrawal
If precipitated withdrawal does occur, defined as an increase in COWS score of 6 or more within two hours of the first buprenorphine dose, there are three options. The first is supportive care with anti-nausea medications, anti-inflammatories, and sedatives while reassuring the patient that symptoms will gradually subside over 6 to 24 hours. The second, and increasingly favored, approach is to give additional buprenorphine. Rapid dose increases (repeated 8 mg doses with close monitoring) can effectively override the precipitated withdrawal by more fully saturating the opioid receptors. This approach works best in a monitored setting. The third option, used as a last resort, is to abandon buprenorphine and switch to a full agonist like methadone.
A strong therapeutic relationship matters here. Patients who trust their provider are more willing to tolerate the initial discomfort and accept additional buprenorphine doses rather than leaving treatment.
Ongoing Monitoring
Urine drug testing is a standard component of treatment monitoring. Baseline testing before or at the start of treatment confirms the presence of opioids and screens for other substances. After that, periodic testing serves two purposes: verifying that the patient is taking the prescribed buprenorphine (the metabolite norbuprenorphine should be present) and checking for ongoing use of other opioids or illicit substances.
Standard immunoassay screens do not reliably detect buprenorphine, so a specific buprenorphine panel is needed. When results are ambiguous or unexpected, confirmatory testing using gas chromatography/mass spectrometry can differentiate between all opioids, including semisynthetic and synthetic compounds like fentanyl, oxycodone, and buprenorphine itself.
Testing frequency should be individualized. Annual testing is a reasonable minimum for stable patients, while those early in treatment or with ongoing instability may benefit from more frequent, random testing. The emphasis should be on using results as a clinical tool to guide treatment decisions rather than as a punitive measure. Unexpected results are an opportunity to adjust the dose, add counseling, or address an unmet need rather than a reason to discharge a patient from care.
Office-Based vs. Home Induction
Induction can happen in the office, where you observe the patient taking their first doses and monitor withdrawal scores in real time, or at home, where the patient self-administers following detailed written instructions. Office-based induction gives you tighter control and is especially useful for patients you’re less familiar with, those with complicated histories, or those transitioning from long-acting opioids. Home induction works well for motivated, reliable patients using short-acting opioids who can recognize withdrawal symptoms and follow a dosing schedule. Both approaches require thorough patient education beforehand: what withdrawal should feel like before taking the first dose, how long to wait between doses, what precipitated withdrawal looks like, and when to call the clinic.